Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

4.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23Andme Holding Co.

< Previous 1 2 3 4 5 6 7 8 9 Next >
23andMe Reports Second Quarter Fiscal 2024 Financial Results
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe, Inc.
Via GlobeNewswire
23andMe Holding's Return On Capital Employed Overview
Via Benzinga
Recap: 23andMe Holding Q4 Earnings
Via Benzinga
23andMe Holding's Earnings Outlook
Via Benzinga
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe... 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report FY2024 Second Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
The Top 7 Stocks to Own During a Downturn
Investors tend to get jittery in October but these seven stocks to own during a downturn will protect your portfolio 
Via InvestorPlace
23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist
An unidentified hacker reportedly claims to have stolen personal genetic data from millions of 23andMe Holding Co. (NASDAQ: ME) customer accounts, sparking concerns over privacy and security. 
Via Benzinga
Topics Hacking
Exposures Information Security
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies 
From 23andMe, Inc.
Via GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
From 23andMe, Inc.
Via GlobeNewswire
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top 5 Health Care Stocks That May Explode In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63. TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 148.5% to $18.14. 
Via Benzinga
Why Dell Technologies Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 53.4% to $0.2147 in pre-market trading after the company announced it received an Underwriting Clearance Notice for a $70 million coupon. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
From 23andMe, Inc.
Via GlobeNewswire
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Both businesses have a lot to prove. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why 23andMe Holding Stock Plummeted by 13% Today
Investors reacted sharply and not well to the company's inaugural set of fiscal 2024 earnings. 
Via The Motley Fool
23andMe Reports FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of... 
From 23andMe, Inc.
Via GlobeNewswire
3 Gene Testing Stocks to Buy Before They Take Off
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.